Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Background: Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. Of these 2754 were Dutch patients. The current study aims for the first time to correlate the ten-year clinical outcomes with predictions by CanAssist Breast (CAB)—a prognostic test developed in South East Asia, on a Dutch sub-cohort that participated in the TEAM. The total Dutch TEAM cohort and the... Mehr ...
Verfasser: |
Zhang, Xi
Gunda, Aparna
Kranenbarg, Elma Meershoek Klein
Liefers, Gerrit Jan
Savitha, Badada Ananthamurthy
Shrivastava, Payal
Serkad, Chandra Prakash Vijay Kumar
Kaur, Taranjot
Eshwaraiah, Mallikarjuna Siraganahalli
Tollenaar, Rob A.E.M.
van de Velde, Cornelis J.H.
Seynaeve, Caroline M.J.
Bakre, Manjiri
Kuppen, Peter J.K. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2023 |
Reihe/Periodikum: |
Zhang , X , Gunda , A , Kranenbarg , E M K , Liefers , G J , Savitha , B A , Shrivastava , P , Serkad , C P V K , Kaur , T , Eshwaraiah , M S , Tollenaar , R A E M , van de Velde , C J H , Seynaeve , C M J , Bakre , M & Kuppen , P J K 2023 , ' Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial ' , Breast Cancer Research , vol. 25 , no. 1 , 40 . https://doi.org/10.1186/s13058-023-01643-2 |
Schlagwörter: |
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
/ name=SDG 3 - Good Health and Well-being |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-27073678 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://pure.eur.nl/en/publications/c98ddee9-d547-45f7-9418-725f71415150 |